AIM ImmunoTech
36 hedge funds and large institutions have $14.7M invested in AIM ImmunoTech in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 5 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
20% more capital inflows, than outflows
Capital inflows: $990K | Capital outflows: $827K
3% more funds holding
Funds holding: 35 → 36 (+1)
0.19% more ownership
Funds ownership: 15.07% → 15.26% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$468K |
| 2 |
Millennium Management
New York
|
+$110K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$81.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.1K |
| 5 |
Winton Group
London,
United Kingdom
|
+$55.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$329K |
| 2 |
Morgan Stanley
New York
|
-$249K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$63K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$52.7K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$44K |
AIM Hedge Fund Activity: Q3 2021 in Review
36 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2021, worth a combined $14.7M — down 4.8% from $15.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AIM positions and 5 closed out — a net gain of 1 holder — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $468K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $329K sold.
- 36 institutional investors held AIM ImmunoTech (AIM) as of Q3 2021, up from 35 in Q2 2021.
- Funds reported $14.7M of AIM ImmunoTech stock for Q3 2021, down 4.8% quarter-over-quarter.
- 6 funds opened new AIM ImmunoTech positions in Q3 2021 and 5 closed out, a net change of +1 holder.
- The largest AIM ImmunoTech buyer in Q3 2021 was Dimensional Fund Advisors, an estimated $468K added.
- The largest AIM ImmunoTech seller in Q3 2021 was Renaissance Technologies, an estimated $329K sold.
Based on aggregated 13F filings for Q3 2021.